TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tryptamine Therapeutics ( (AU:TYP) ) just unveiled an announcement.
Tryptamine Therapeutics Limited has released a corrected Quarterly Activities Report for September 2025, highlighting changes in the use of funds. The report details actual cash outflows and material variances, including the completion of various clinical trials and manufacturing activities. Notably, the TRP-8803 dosing study in Australia saw increased subject numbers and additional equipment purchases, which are expected to reduce future trial costs. The company also initiated a new trial for binge eating disorder at Swinburne University. These developments reflect Tryptamine’s ongoing commitment to advancing its clinical programs and strengthening its market position in the biotechnology sector.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations for administering psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company’s lead program, TRP-8803, is an IV-infused psilocin formulation aimed at improving the administration of psilocybin by reducing the time to onset, controlling the psychedelic experience, and shortening the intervention duration. Tryptamine has completed Phase 2a trials for binge eating disorder and fibromyalgia, showing significant results.
Average Trading Volume: 2,375,817
Technical Sentiment Signal: Buy
Current Market Cap: A$54.87M
Find detailed analytics on TYP stock on TipRanks’ Stock Analysis page.